Celgene (Warren, NJ), a developer of chirally pure drugs, agreed on June 30 to purchase gene-regulation firm Signal Pharmaceuticals (San Diego, CA) for $200 million in an all-stock deal.

Celgene Corporation, an international drug manufacturer, and its subsidiary Celgene Logistics have been referred for prosecution by the Competition Commission to the Competition Tribunal for the ...

Celgene shows no sign of slowing down on the deal-making front as its merger with Bristol-Myers Squibb draws nearer. Its latest – with Immatics – bolsters its immuno-oncology business and ...